| 摘要 |
<p>The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)</p> |
| 申请人 |
SCHERING CORPORATION;SHIPPS, JR., GERALD, W.;CHENG, CLIFF, C.;HUANG, XIAOHUA;ACHAB, ABDELGHANI, ABE;ORTH, PETER;VOIGT, JOHANNES, H.;SOUCY, KYLE, ANN |
发明人 |
SHIPPS, JR., GERALD, W.;CHENG, CLIFF, C.;HUANG, XIAOHUA;ACHAB, ABDELGHANI, ABE;ORTH, PETER;VOIGT, JOHANNES, H.;SOUCY, KYLE, ANN |
